$NKTR
Nektar Therapeutics

2024 Q4 Form 10-Q Financial Statement

#000095017024123570 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $24.12M
YoY Change -0.08%
Cost Of Revenue $4.435M
YoY Change -64.32%
Gross Profit $19.69M
YoY Change 68.1%
Gross Profit Margin 81.62%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $35.03M
YoY Change 45.54%
% of Gross Profit 177.92%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $35.03M
YoY Change 45.54%
Operating Profit -$34.35M
YoY Change -23.45%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.703M
YoY Change 161.41%
Pretax Income -$37.05M
YoY Change -19.28%
Income Tax $9.000K
% Of Pretax Income
Net Earnings -$37.06M
YoY Change -19.15%
Net Earnings / Revenue -153.61%
Basic Earnings Per Share -$0.18
Diluted Earnings Per Share -$0.18
COMMON SHARES
Basic Shares Outstanding 184.5M 184.1M
Diluted Shares Outstanding 209.2M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $244.5M
YoY Change -34.39%
Cash & Equivalents $30.11M
Short-Term Investments $214.4M
Other Short-Term Assets $8.933M
YoY Change -1.11%
Inventory $0.00
Prepaid Expenses
Receivables $0.00
Other Receivables
Total Short-Term Assets $286.5M
YoY Change -28.2%
LONG-TERM ASSETS
Property, Plant & Equipment $3.603M
YoY Change -81.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.519M
YoY Change -0.09%
Total Long-Term Assets $21.49M
YoY Change -50.29%
TOTAL ASSETS
Total Short-Term Assets $286.5M
Total Long-Term Assets $21.49M
Total Assets $308.0M
YoY Change -30.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.577M
YoY Change 160.86%
Accrued Expenses $32.38M
YoY Change 8.91%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $67.58M
YoY Change 29.69%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $6.912M
YoY Change 39.33%
Total Long-Term Liabilities $6.912M
YoY Change 39.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $67.58M
Total Long-Term Liabilities $6.912M
Total Liabilities $259.1M
YoY Change -8.41%
SHAREHOLDERS EQUITY
Retained Earnings -$3.603B
YoY Change 4.9%
Common Stock $3.655B
YoY Change 1.5%
Preferred Stock
YoY Change
Treasury Stock (at cost) $3.000M
YoY Change
Treasury Stock Shares
Shareholders Equity $48.88M
YoY Change
Total Liabilities & Shareholders Equity $308.0M
YoY Change -30.36%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$37.06M
YoY Change -19.15%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000906709
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-24006
dei Entity Registrant Name
EntityRegistrantName
NEKTAR THERAPEUTICS
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3134940
dei Entity Address Address Line1
EntityAddressAddressLine1
455 Mission Bay Boulevard South
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
482-5300
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
NKTR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
184458284
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30109000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35277000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
214386000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
268339000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1205000
CY2024Q3 us-gaap Inventory Net
InventoryNet
0
CY2023Q4 us-gaap Inventory Net
InventoryNet
16101000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
8933000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9779000
CY2024Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
33053000
CY2023Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2024Q3 us-gaap Assets Current
AssetsCurrent
286481000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
330701000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4537000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
25825000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3603000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18856000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
8826000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18007000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4519000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4644000
CY2024Q3 us-gaap Assets
Assets
307966000
CY2023Q4 us-gaap Assets
Assets
398033000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8577000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9848000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32377000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22162000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21504000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19259000
CY2024Q3 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
5125000
CY2023Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
0
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
67583000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51269000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
86758000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
98517000
CY2024Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
97829000
CY2023Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current Net Of Issuance Costs
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrentNetOfIssuanceCosts
112625000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
6912000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4635000
CY2024Q3 us-gaap Liabilities
Liabilities
259082000
CY2023Q4 us-gaap Liabilities
Liabilities
267046000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2023Q4 nktr Preferred Stock Share Designated
PreferredStockShareDesignated
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
192743000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
191384000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
184458000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
191384000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
19000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3654981000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3608137000
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
8285000
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
3000000
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
355000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
80000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3603471000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3477249000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
48884000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
130987000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
307966000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
398033000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24124000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
24144000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
69252000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
66237000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4435000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12431000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
22709000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26485000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35031000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24070000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
92163000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84220000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18957000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21147000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
59616000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
60097000
CY2024Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
46000
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
11360000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
14310000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
49107000
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
CY2024Q3 us-gaap Costs And Expenses
CostsAndExpenses
58469000
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
69008000
us-gaap Costs And Expenses
CostsAndExpenses
188798000
us-gaap Costs And Expenses
CostsAndExpenses
296410000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34345000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-44864000
us-gaap Operating Income Loss
OperatingIncomeLoss
-119546000
us-gaap Operating Income Loss
OperatingIncomeLoss
-230173000
CY2024Q3 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
6020000
CY2023Q3 nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
5910000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
17959000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
18467000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3437000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
5211000
us-gaap Investment Income Interest
InvestmentIncomeInterest
11558000
us-gaap Investment Income Interest
InvestmentIncomeInterest
14392000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-120000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-335000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-255000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
100000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2703000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1034000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6656000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3975000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-37048000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-45898000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-126202000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-234148000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-61000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-171000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-37057000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45837000
us-gaap Net Income Loss
NetIncomeLoss
-126222000
us-gaap Net Income Loss
NetIncomeLoss
-233977000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.23
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
209249000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
209249000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
190406000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
190406000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
204292000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
204292000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
189651000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
189651000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-37057000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-45837000
us-gaap Net Income Loss
NetIncomeLoss
-126222000
us-gaap Net Income Loss
NetIncomeLoss
-233977000
CY2024Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
877000
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
196000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
312000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1527000
CY2024Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-28000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-98000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-37000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-972000
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
849000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
98000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
275000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
555000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36208000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45739000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-125947000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-233422000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
366638000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10019000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-135792000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
240865000
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
18000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7966000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-51891000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
196958000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8149000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45739000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
159368000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
130987000
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6000000
CY2024Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
3000000
CY2024Q1 nktr Issuance Of Prefunded Warrant
IssuanceOfPrefundedWarrant
30000000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-37285000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
126705000
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
19000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5418000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52454000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
79688000
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
13000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5391000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-36208000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
48884000
us-gaap Profit Loss
ProfitLoss
-126222000
us-gaap Profit Loss
ProfitLoss
-233977000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
48029000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
50860000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
17959000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
18467000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16809000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26134000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
4059000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6163000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-12000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-1854000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
8329000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36628000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76501000
nktr Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
20000
nktr Provision For Inventory Obsolescence
ProvisionForInventoryObsolescence
4444000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
7711000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
12137000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
841000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3777000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
808000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
372000
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
7620000
nktr Increase Decrease In Operating Lease Right Of Use Assets Net Of Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseRightOfUseAssetsNetOfOperatingLeaseLiabilities
6078000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1761000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-4450000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1023000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-9328000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
17329000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-7517000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-129522000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-145559000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
191882000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
372821000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
275247000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
494385000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1009000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
628000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1245000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
82356000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
122181000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
35000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
18000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
30000000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
nktr Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
15000000
nktr Proceeds From Sale Of Future Royalties
ProceedsFromSaleOfFutureRoyalties
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
3000000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42035000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-37000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5168000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23306000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
35277000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
88227000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30109000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64921000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2656000
CY2024Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
249000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:5.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Actual results could differ materially from those estimates and assumptions. As appropriate, we assess estimates each period, update them to reflect current information, and generally reflect any changes in estimates in the period first identified.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Significant Concentrations</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our customers are primarily pharmaceutical companies that are located in the U.S. and Europe and with whom we have multi-year arrangements. Our accounts receivable balances contain billed and unbilled trade receivables from product sales, milestones (to the extent that they have been achieved and are due from the counterparty), and other contingent payments, as well as reimbursable costs from collaborative research and development agreements. We generally do not require collateral from our customers. We perform a regular review of our customers’ credit risk and payment histories, including payments made after period end. Historically, we have </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">t experienced credit losses from our accounts receivable or contract assets. We have not recorded reserves for credit losses for the </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three and nine months ended September 30, 2024 and 2023, nor have recorded such an allowance as of September 30, 2024 or December 31, 2023. As of September 30, 2024, all billed and unbilled trade receivables from product sales and contract assets have been classified as held-for-sale and included within assets held for sale on our Condensed Consolidated Balance Sheets.</span></p><p style="text-indent:5.84%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are dependent on our suppliers and contract manufacturers to provide raw materials and drugs of appropriate quality and reliability and to meet applicable contract and regulatory requirements. In certain cases, we rely on single sources of supply of one or more critical materials. Consequently, in the event that supplies are delayed or interrupted for any reason, our ability to develop and produce our drug candidates or our ability to meet our supply obligations could be significantly impaired, which could have a material adverse effect on our business, financial condition and results of operations.</span></p><p style="text-indent:5.867%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">For our available-for-sale securities, we have significant concentrations of issuers in the banking and financial services industries. While our investment policy requires that we only invest in highly-rated securities and limit our exposure to any single issuer, various factors may materially affect the financial condition of issuers. Additionally, pursuant to our investment policy, we may sell securities before maturity if the issuer’s credit rating has been downgraded below our minimum credit rating requirements, which may result in a loss on the sale. Accordingly, if various factors result in downgrades below our minimum credit rating requirements and if we decide to sell these securities, we may experience losses on such sales.</span></p>
CY2024Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2023Q3 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30109000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35277000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
214386000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
268339000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4537000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
25825000
CY2024Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
249032000
CY2023Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
329441000
CY2024Q3 us-gaap Cash
Cash
6247000
CY2023Q4 us-gaap Cash
Cash
17843000
CY2024Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
249032000
CY2023Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
329441000
CY2024Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
0
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1861000
CY2024Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
0
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
12880000
CY2024Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
0
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1360000
CY2024Q3 us-gaap Inventory Net
InventoryNet
0
CY2023Q4 us-gaap Inventory Net
InventoryNet
16101000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
8933000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9779000
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Accounts Notes And Loans Receivable Net
DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
1746000
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Inventory Current
DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
16889000
CY2024Q3 us-gaap Disposal Group Including Discontinued Operation Property Plant And Equipment Current
DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
11386000
CY2024Q3 nktr Disposal Group Including Discontinued Operation Contract With Customer Asset Current
DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent
3032000
CY2024Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
33053000
CY2024Q3 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
19124000
CY2023Q4 nktr Depreciable Property Plant And Equipment Gross
DepreciablePropertyPlantAndEquipmentGross
105015000
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15659000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
86898000
CY2024Q3 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
3465000
CY2023Q4 nktr Depreciable Property Plant And Equipment Net
DepreciablePropertyPlantAndEquipmentNet
18117000
CY2024Q3 us-gaap Construction In Progress Gross
ConstructionInProgressGross
138000
CY2023Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
739000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3603000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18856000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7007000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5553000
CY2024Q3 nktr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
17916000
CY2023Q4 nktr Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
10118000
CY2024Q3 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3151000
CY2023Q4 nktr Accrued Contract Termination Costs Current
AccruedContractTerminationCostsCurrent
3020000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
4303000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3471000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32377000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
22162000
CY2023Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
112625000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
48029000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
17959000
nktr Liabilities On Sale Of Future Royalties Amortized Transaction Costs
LiabilitiesOnSaleOfFutureRoyaltiesAmortizedTransactionCosts
274000
nktr Proceeds From Amendment Related To Sales Of Future Royalties Net
ProceedsFromAmendmentRelatedToSalesOfFutureRoyaltiesNet
15000000
CY2024Q3 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
97829000
CY2024Q3 us-gaap Litigation Reserve
LitigationReserve
0
CY2023Q4 us-gaap Litigation Reserve
LitigationReserve
0
CY2024Q3 nktr Disposal Group Including Discontinued Operation Contract With Customer Asset Current
DisposalGroupIncludingDiscontinuedOperationContractWithCustomerAssetCurrent
3000000
CY2024Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
0
CY2023Q3 us-gaap Business Exit Costs1
BusinessExitCosts1
652000
us-gaap Business Exit Costs1
BusinessExitCosts1
0
us-gaap Business Exit Costs1
BusinessExitCosts1
3606000
CY2024Q3 us-gaap Severance Costs1
SeveranceCosts1
0
CY2023Q3 us-gaap Severance Costs1
SeveranceCosts1
535000
us-gaap Severance Costs1
SeveranceCosts1
0
us-gaap Severance Costs1
SeveranceCosts1
7961000
CY2024Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
10173000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
8329000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36628000
CY2024Q3 us-gaap Loss On Contract Termination
LossOnContractTermination
46000
CY2023Q3 us-gaap Loss On Contract Termination
LossOnContractTermination
0
us-gaap Loss On Contract Termination
LossOnContractTermination
5981000
us-gaap Loss On Contract Termination
LossOnContractTermination
912000
CY2024Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
46000
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
11360000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
14310000
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
49107000
CY2024Q1 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
CY2024Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
8329000
CY2023Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
10567000
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
394000
CY2023Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
10173000
nktr Property Plant And Equipment And Operating Lease Right Of Use Asset Book Value In Excess Of Fair Value
PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetBookValueInExcessOfFairValue
36962000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1633000
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
35329000
nktr Impairment Long Lived Asset Held For Use Other
ImpairmentLongLivedAssetHeldForUseOther
1299000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
36628000
nktr Impairment Of Remaining Long Lived Asset Held For Use
ImpairmentOfRemainingLongLivedAssetHeldForUse
0
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
76500000
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5391000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8149000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16809000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26134000

Files In Submission

Name View Source Status
0000950170-24-123570-index-headers.html Edgar Link pending
0000950170-24-123570-index.html Edgar Link pending
0000950170-24-123570.txt Edgar Link pending
0000950170-24-123570-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nktr-20240930.htm Edgar Link pending
nktr-20240930.xsd Edgar Link pending
nktr-ex31_1.htm Edgar Link pending
nktr-ex31_2.htm Edgar Link pending
nktr-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nktr-20240930_htm.xml Edgar Link completed
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending